Register your interest
Below and on the next page are questions to help discover whether you may be eligible to participate in the University of Sydney trial.
By completing this online form you agree that your information will be collected and stored by SFI Research for the purposes of assessing your potential eligibility for the trial. Should you be eligible for the trial, a representative from University of Sydney will call you to ask you a few more questions about your medical history.
Are you overweight and have an elevated blood sugar level?
Are you based in Sydney?
If so, you are invited to take part in a diabetes prevention study comparing dietary supplements to aid in weight loss and blood sugar control.
Lead researchers at Charles Perkins Centre (Dr Nicholas Fuller and Clinical Associate Professor Tania Markovic) are seeking participants interested in weight loss and preventing diabetes for a double blinded, randomised controlled trial to determine the efficacy of FBCx® (a formula based on α-cyclodextrin) on cholesterol, and the efficacy of GINST15™ (a ginseng extract formula) on glycaemic control.
Over a period of 12 months, you will receive dietary supplements and weight loss advice from our dietitians, psychologists and exercise physiologists at no cost to you.
Products being investigated
- FBCx® is a polysaccharide (a complex sugar) derived from corn. It has been demonstrated to prevent the absorption of dietary fat. FBCx® is effective in reducing and/or maintaining a healthy body weight. Studies also suggest FBCx® may increase insulin sensitivity and improve cholesterol and triglyceride levels in people with high levels of triglycerides.
- GINST15™: The root of ginseng has long been used in traditional Chinese medicine, most recently for improving glycaemic control. GINST15™ has been shown to be the active ingredient in ginseng for this anti-diabetic action.
It is proposed that these products may overlap in their function and therefore are being compared in the same study for the prevention of type 2 diabetes.
Should you agree to participate in this study, you will be asked to sign the Participant Consent Form at a “screening” visit. You will then be asked to undergo the following procedures:
- Measurement of height, body weight, and waist circumference
- Recording of your medical history (including any forthcoming procedures)
- Recording of any medications you are currently taking
- Measurement of blood pressure and heart rate
- Electrocardiogram (ECG)
- Collection of a 50 mL blood sample
- Handgrip strength test
- Dexa scan (a full body composition scan)
- Urine collection (for women of child bearing potential only)
- Completion of questionnaires
Healthcare practitioner trial information
University of Sydney Boden Institute Clinical Associate Professor Tania Markovic leads the trial as Principal Investigator.
This trial is being sponsored by The University of Sydney and conducted at The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders Charles Perkins Centre, D17 Johns Hopkins Drive, Camperdown, NSW 2006 and Nepean Hospital.
This study has been approved by the Ethics Review Committee (Royal Prince Alfred Hospital Zone) of the Sydney Local Health District.
Study Trial No.: ACTRN12614001302640
For more Information
For more information about the trial or clinical papers on the products being investigated, please email email@example.com or call (02) 6431 7213
All the information collected from you for the study will be treated confidentially, and only the research institute will have access to it. The study results may be presented at a conference or in a scientific publication, but individual participants will not be identifiable in such a presentation.
FBCx® and GINST15™ clinical papers
Please find below clinical research papers on FBCx® and GINST15™
- Comerford K, et al. 2011: The Beneficial Effects α-Cyclodextrin on Blood Lipids and Weight Loss in Healthy Humans
- Jarosz et al. 2013: The Effect of α-Cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal
- Wagner EM et al. 2008: Dietary α-cyclodextrin lowers low-density lipoprotein cholesterol in low-density lipoprotein receptor knockout mice on a high-fat diet
Confirming your eligibility
The information below regarding your health will not be stored and only used to assess trial enrolment eligibility
Have you been diagnosed with Type 1 or Type 2 Diabetes by a doctor?
- Please provide your height and weight
- Are you currently taking any of the following medications:
- Medication to lower blood sugar
- Medication to lower cholesterol
- Weight loss medications or other drugs affecting weight (e.g. corticosteroids)
Are you willing to take two tablets before and after each meal?
- Have you ever had cancer?
Please choose the answer that best describes you:
Are you willing and/or able to attend regular appointments at either the Charles Perkins Centre, opposite Royal Prince Alfred Hospital OR Nepean Hospital?
- If you are eligible following this screening questionnaire, what is the best time to call you?
Day of weekTime slot
How did you hear about this trial?